Concourse Financial Group Securities, Inc. Lava Therapeutics Nv Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$1.8 - $3.37 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.53 - $4.03 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.17 - $1.58 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.47 - $2.06 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.47 - $2.06 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.4 - $2.6 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.59 - $3.97 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$3.4 - $7.31 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.34 - $3.15 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.28 - $4.4 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.28 - $6.55 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.23 - $7.77 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$5.5 - $11.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$10.8 - $16.0 $0 - $0
Q1 2021 May 13, 2021	BUY	$12.5 - $15.19 $0 - $0

Others Institutions Holding LVTX

# of Institutions

Shares Held

3.76M

Call Options Held

85.8K

Put Options Held

36.8K

View Full List

About LAVA Therapeutics NV

Ticker LVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,797,700
Market Cap $42.3M
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...

More about LVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account